Global E Online Ltd vs Revvity Inc — how do they compare? Global E Online Ltd trades at $40.24 (market cap $6.75B), while Revvity Inc trades at $154.16 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.5× Global E Online Ltd's market cap, and Revvity Inc pays a 0.18% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Revvity Inc for 12 Days on average.
| GLBE | RVTY | |
|---|---|---|
Market Cap | $6.75B | $16.98B |
Volume | 1,468,708 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $157.36 |
52-Week Low | $27.54 | $82.26 |
Typical Hold Time | 21 Days | 12 Days |
Enterprise Value | $6.24B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.22, up 3.23% with strong analyst support (14 buys, 1 hold). The stock shows bullish technical momentum above key support at $40, while fundamentals reveal robust revenue growth from $962M in 2025 to $1.1B projected for 2026. Recent Q2 earnings beat expectations with 44% GMV growth, though insider selling and elevated P/E of 45.65 warrant caution.
Outlook remains positive given raised 2026 guidance and 28% upside to consensus target of $48.86. Key risks include valuation sensitivity to growth execution and persistent insider selling. The appointment of a new Chief Revenue Officer signals strategic focus on scaling, but investors should monitor quarterly execution against elevated expectations.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
Latest headlines on both assets
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →